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pital-acquired pneumonia (HAP) represents more than 25% of 
all infections in the ICU; hospital stays and health costs are 
very high, with a mortality rate between 27% and 50% [6]. 
The microbiological diagnosis is generally difficult to establish, 
including when complex and invasive diagnostic methods are 
used. In fact, microbiological confirmation is achieved in less 
than half of the cases and the initial antibiotic regimen must 
be empirically chosen to prevent delays in establishing an ap-
propriate treatment, which is associated with elevated mortal-
ity [7–10].
Streptococcus pneumoniae (pneumococcus) continues to 
be the most common cause of CAP in all patient treatment 
settings (outpatient, hospitalized and patients admitted into 
intensive care units), age groups, and regardless of the pa-
tient’s comorbidities [11].
However, it is reported that approximately 6% of CAP is 
caused by antibiotic-resistant pathogens, with Pseudomonas 
aeruginosa and methicillin-resistant Staphylococcus aureus 
(MRSA) being the most common [12]. 
In cases of pneumonia due to influenza virus, pneumo-
coccus is the most commonly identified pathogen in patients 
with bacterial co-infection. However, other pathogens such as 
S. aureus (methicillin-susceptible or resistant), Haemophilus 
influenzae and non-fermenting Gram-negative bacilli such as 
P. aeruginosa have also been reported. In patients with severe 
CAP, P. aeruginosa has been identified in 8.3% of patients, 
with a mortality rate of up to 100% [9, 13]
In HAP, the most common infecting bacteria are mem-
bers of the Enterobacteriaceae family (such as Klebsiella spp., 
Enterobacter spp., Serratia spp.), S. aureus, P. aeruginosa, and 
Acinetobacter baumannii, the majority of these microorgan-
isms being multi-drug resistant, highlighting their importance 
in the current challenge of antibiotic resistance [14]. 
Ceftobiprole, a fifth-generation (last generation) extend-
ed-spectrum cephalosporin, shows potent in vitro activity 
against several Gram-positive pathogens, including methi-
ABSTRACT 
Ceftobiprole is a fifth-generation cephalosporin with 
potent antimicrobial activity against Gram positive and 
Gram-negative bacteria. It has been approved in major Eu-
ropean countries for the treatment of community-acquired 
pneumonia (CAP) and hospital-acquired pneumonia (HAP), ex-
cluding ventilator-associated pneumonia (VAP). Ceftobiprole is 
currently in a phase 3 clinical program for registration in the 
U.S. In 2015, it was designated as an infectious disease prod-
uct qualified for the treatment of lung and skin infections by 
the FDA. The efficacy of ceftobiprole in pneumonia has been 
demonstrated in two-phase III clinical trials conducted in pa-
tients with CAP and HAP. The recommended dose in the adult 
with pneumonia is 500 mg every 8 h infused in 2 h; in case of 
renal failure, the regimen of administration must be adjusted 
according to the patient’s renal function. It is not necessary to 
adjust the dose according to gender, age, body weight or liver 
failure. In case of hyperfiltration, an extension to 4 h infusion 
of the 500mg TID is required.
INTRODUCTION
Pneumonia is a serious health problem and a significant 
cause of morbidity and mortality around the world despite ad-
vances in clinical treatment and antibiotic therapy [1]. Com-
munity-acquired pneumonia (CAP) is associated with elevated 
health costs and is a common cause of emergency care and 
hospital admissions, especially in elderly patients and those 
with multiple comorbidities, whose mortality rate (which is ap-
proximately 10%) may reach 40% in cases of severe CAP that 
requires treatment in the intensive care unit (ICU) [2–5]. Hos-
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for adding linezolid. Primary endpoint was the clinical cure 
rate at the TOC visit on the intent-to-treat (ITT) and clinically 
evaluable (CE) population. The secondary efficacy criteria were 
microbiological eradication rate at TOC visit, the rate of clinical 
recovery according to the baseline PSI in ITT and CE popula-
tions, and specific mortality due to pneumonia after 30 days in 
ITT and CE populations. The pre-defined non-inferiority margin 
of 10% (95% CI) was set for all endpoints.
The study demonstrated that ceftobiprole (500 mg/8 h in-
fused in 2 h) was not inferior to ceftriaxone (2 g/24 h), whether 
as monotherapy or combined with linezolid (600 mg/12 h). No 
difference was found in the overall clinical and microbiological 
analyses, as well as in predefined high-risk subgroups or other 
subgroups of interest (including those treated with antistaph-
ylococcal agents). For all 469 clinically evaluable patients, the 
recovery rates were 86.6% versus 87.4%, respectively; in the 
intent-to-treat (IIT) analysis of 638 patients with CAP, the re-
covery rate was 76% versus 79%, respectively [17] (figure 1).
For the secondary criterion of microbiological eradication, 
non-inferiority between ceftobiprole and the comparator was 
established. Specific mortality due to pneumonia in the first 
30 days was very low, both for the ceftobiprole group and the 
ceftriaxone ± linezolid (1 versus 3 patients in the ITT popula-
tion and 0 versus 2 patients in the CE population).
Clinical trial on HAP. Similar to the first study, the sec-
ond was a phase-III , multi-national, randomised, double-blind 
study that compared ceftobiprole against the combination of 
ceftazidime plus linezolid in 781 adults with HAP (defined as 
a pneumonia arising after >72 h of hospitalization or stay in a 
cillin-susceptible S. aureus (MSSA), MRSA with reduced sus-
ceptibility to linezolid, daptomycin or vancomycin, methicil-
lin-resistant coagulase-negative staphylococci (MR-CoNS), 
penicillin- and ceftriaxone-resistant S. pneumoniae, along 
with in vitro activity Gram-negative pathogens including P. 
aeruginosa and non-extended-spectrum beta-lactamases (ES-
BL)-producing Enterobacteriaceae [15] (table 1). Ceftobipro-
le has shown to have a time-dependent bactericidal activity, 
as expected by this class of molecules. It exerts its action by 
blocking the transpeptidase activity in penicillin-binding pro-
teins (PBP) both in Gram-positive and Gram-negative patho-
gens. As a result, peptidoglycan synthesis decreases and the 
bacteria die due to the osmotic effects or by autolytic enzyme 
digestion [16]. 
CLINICAL EFFICACY IN PATIENTS WITH 
PNEUMONIA
The safety and efficacy of ceftobiprole medocaril has been 
investigated in two phase-III clinical trials in patients with CAP 
and HAP [17, 18].
Clinical trial on CAP. This was a multi-centre, dou-
ble-blind, randomised study on 638 patients with CAP who re-
quired hospitalization, ceftobiprole (500 mg/8h) was compared 
to ceftriaxone (2g/day) with or without linezolid (if suspect-
ed MRSA infection, 600 mg/12h). Linezolid was administered 
in patients with suspected MRSA or ceftriaxone-resistant S. 
pneumoniae. Patients were stratified according to severity 
measured by the Pneumonia Severity Index (PSI) and by need 
ACTIVE
Gram-positive bacteria








Proteus mirabilis Non-extended-spectrum beta-lactamase (ESBL)-producing
INACTIVE
Strains of Enterobacteriaceae that express Amber class A beta lactamases, especially TEM, SHV and CTX-M types, as well as KPC-type carbapenemases; it is also 
inactive against Amber class B, C (high levels of expression) and D, particularly the ESBL variants and OXA-48 carbapenemases.
Strains of beta-lactamase-producing Pseudomonas aeruginosa from classes A (PSE-1), B (IMP-1, VIM-1, VIM-2) and D (OXA-10).
Strains of beta-lactamase-producing Acinetobacter spp. from classes A (VEB-1), B (IMP-1, IMP-4) and D (OXA-25, OXA-26)
Table 1  Ceftobiprole’s antibiotic activity
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of 15% for the 95% CIs. The secondary criteria were microbio-
logical eradication at the TOC visit in ITT and microbiologically 
evaluable populations with a valid pathogen at baseline, 30-
day all-cause mortality in the ITT population, as well as safety 
and tolerability.
For the primary efficacy criteria, the study demonstrated 
that treatment with ceftobiprole monotherapy (500 mg/8 h 
infused in 2 h) was non-inferior to a combined treatment that 
included ceftazidime (2 g/8 h) plus linezolid (600 mg/12 h) for 
patients with HAP, excluding patients with VAP. In the CE pop-
ulation, 86.9% of patients with HAP (excluding patients with 
VAP) in the ceftobiprole group demonstrated early improve-
ment (4 days after beginning therapy); compared to 78.4% 
in the ceftazidime plus linezolid group (difference 8.5 [CI of 
95%, 0.9–16.1]). A major numerical difference was observed 
in the subgroup of patients with microbiological evidence of 
MRSA infection (94.7% in the ceftobiprole group vs. 52.6% in 
the ceftazidime group plus linezolid (difference, 42.1 [CI 95%, 
17.5–66.7]). For the secondary efficacy criteria, the microbio-
long-term care unit). The inclusion criteria were: clinical signs 
and symptoms of pneumonia (at least two including purulent 
respiratory secretion, tachypnoea, or hypoxemia); fever or leu-
kocytosis/leukopenia; new or persistent radiographic infiltrates; 
and an APACHE II score of 8-25. The exclusion criteria were: 
severe kidney or liver failure; evidence of infection due to cef-
tobiprole or ceftazidime-resistant pathogens; clinical conditions 
that could interfere with the efficacy evaluation (for example, 
sustained shock, active tuberculosis, pulmonary abscess, and 
post-obstructive pneumonia); and systemic antibiotic treatment 
for >24 h in the 48 h prior to inclusion. Patients were stratified 
for treatment according to presence of VAP (pneumonia aris-
ing after >48 h after the start of mechanical ventilation) and 
APACHE II score (8–19/20–25); VAP patients were stratified ac-
cording to length of mechanical ventilation (</≥5 days).
The primary efficacy endpoint was the clinical cure rate 
at the TOC visit (7 to 14 days after the last dose of the study 
drug or early termination) in the ITT and clinically evaluable 
(CE) populations; non-inferiority was defined using a margin 
Figure 1  CAP: Percentage of clinical efficacy in the population by intention to treat (A) and in clinically 
evaluable population (B)
(A) (B)
Figure 2  HAP: Percentage of patients with clinical cure visit of cure test in the population by intention to treat 
(A) and in clinically evaluable population (B)
(A) (B)
Differences between groups -2.0% (-10.0–6.1) 1.6% (-6.9–10.0) -18.2% (-36.4 to -0.0) 
IC 95%
Differences between groups -2.9% (-10.0–4.1) 0.8% (-7.3–8.8) -13.7% (-26.0 to -1.5) 
IC 95%
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VAP was different from patients without VAP, which may be 
attributed to increased cardiac output, augmented glomerular 
filtration rate, and increased volume of distribution associated 
with critical illness. For this reason, it is unlikely that ceftobi-
prole will meet the desired PD objectives when the PK param-
eters are altered. Indeed, for patients hospitalized in the ICU 
with creatinine clearance (CrCl) >150 ml/min, extending the 
ceftobiprole infusion time to 4 h contributes to keep plasma 
levels above the minimum inhibitory concentration (MIC) (4 
mg/L). As such, for patients with increased kidney function (Cr-
Cl>150 ml/min), increasing the duration of ceftobiprole infu-
sion is recommended (500 mg for 4 h/8 h), according to linear 
PK and low protein binding [19].
The inferior outcome of ceftobiprole in VAP may have 
been the result of suboptimal concentrations of ceftobiprole 
at the infection site as a result of the change in volume of 
distribution due to mechanical ventilation capillary filtration. 
Ceftobiprole has so far demonstrated a good safety profile 
in preliminary studies, with a tolerance similar to that of com-
parators. The most commonly observed adverse events with 
ceftobiprole include headache and gastrointestinal disorders. 
Ceftobiprole is the first cephalosporin monotherapy that has 
been approved in Europe for the treatment of CAP and HAP, ex-
cluding VAP. Ceftobiprole is not approved by the Food and Drug 
Administration (FDA); however in 2015 it was designated as an 
infectious disease product qualified for the treatment of lung 
and skin infections by the FDA [20]. There is an ongoing phase III 
study at this time to compare the safety and efficacy of ceftobi-
prole medocaril versus vancomycin plus aztreonam in the treat-
ment of patients with acute bacterial skin and skin structure 
infections. BARDA program https://clinicaltrials.gov/ct2/show/
NCT03137173?term=Ceftobiprole&draw=3&rank=11 
logical eradication rates at the completion of treatment (CT) 
visit in patients with HAP (excluding VAP) were similar in the 
ceftobiprole and ceftazidime/linezolid groups in the ITT (49% 
versus 54%; difference 5.0; CI 95%: 15.3–5.3) and microbio-
logically evaluable groups (63% vs. 68%; difference -4.6; CI 
95%: -16.7–7.6) (figure 2A). In addition, clinical recovery and 
rates of microbiological eradication of pathogens in patients 
with HAP (excluding VAP) were similar for Gram-positive and 
the majority of Gram-negative microorganisms.
In the overall population, the recovery rates in clinically 
evaluable patients for ceftobiprole compared to ceftazidime/
linezolid were 69.3% vs. 71.3%, respectively. Ceftobiprole nonin-
feriority was not demonstrated in the subgroup of patients with 
VAP patients with recovery rates in the clinically evaluable cases 
of VAP of 37.7% vs. 55.9% [18], respectively (figure 2B). 
Interestingly, in patients with HAP requiring mechanical 
ventilation for less than 48 h, thus not defined as VAP, clinical 
outcomes favoured ceftobiprole, suggesting that mechanical 
ventilation itself may not be associated with poor outcomes, 
whereby ceftobiprole may be administered in patients with 
HAP requiring mechanical ventilation. There are different ex-
planations for ceftobiprole outcomes observed in the VAP 
subgroup of patients: the small sample size and considerable 
heterogeneity of baseline clinical characteristics in the VAP 
subgroup may have contributed to the difference in outcomes 
(figure 3) [19]. 
Furthermore, out of the 16 (62.5%) patients ≤45 years 
with VAP and cranial trauma who were randomized into the 
ceftobiprole group, 12 (17.6%) were characterized as treat-
ment failures compared to two out of four assigned to the cef-
tazidime/linezolid group. 
The pharmacokinetics (PK) of ceftobiprole in patients with 
Figure 3  Clinical characteristics between groups: HAP (excluding VAP) ceftobiprole, 
HAP (excluding VAP) ceftazidime/linezolid, VAP ceftobiprole, VAP 
ceftazidima/linezolid
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groups. The volume of distribution and total clearance of cefto-
biprole were 25.9 and 19.1% higher, respectively, in those who 
were severely obese compared to non-obese individuals; exposure 
to ceftobiprole was lower in adults who were severely obese than 
in those who were not. Plasma concentrations of unbound cef-
tobiprole remained above the MIC objective of 4 mg/L (fT >MIC) 
for 76.6 and 79.7% of an 8 h. dose interval in severely obese and 
non-obese individuals, respectively. Although the volume of dis-
tribution and total clearance were higher and exposure was lower 
in adults with severe obesity compared to non-obese individuals 
after a ceftobiprole infusion, the % fT >MIC was similar in both 
groups, which indicates that it’s not necessary to adjust the dose 
of ceftobiprole in patients with severe obesity [24].
TOLERABILITY 
With respect to the tolerability of ceftobiprole, one po-
tential benefit of kidney excretion is that it may limit exposure 
to antibiotics in the intestine, although to date there are no 
studies that specifically address this topic. Only one study pub-
lished in 2010 investigated the effect of the administration of 
ceftobiprole on the normal intestinal microflora of 12 healthy 
subjects aged 20 to 31 years who received ceftobiprole 500 
mg via intravenous infusion every 8 h for 7 days. This study 
showed that ceftobiprole achieves low levels of intestinal ex-
posure, with only minor effects on the intestinal microbiota. 
In fact, no measurable concentrations of ceftobiprole were 
detected in faeces following intravenous administration in 
healthy volunteers and no Clostridium difficile strains or toxins 
were found. Also, one study on mice showed that ceftobiprole 
did not promote the growth of C. difficile in faecal content 
and was not associated with toxin production. 
Ceftobiprole in CAP and HAP (excluding VAP). Due 
to its safety profile and good antibiotic activity against an 
extended spectrum of pathogens in CAP, especially penicillin- 
and ceftriaxone-resistant S. pneumoniae, as well as S. aureus 
especially MRSA, ceftobiprole may be a very good therapeutic 
option for patients with risk factors for infection caused by 
these pathogens. Also, ceftobiprole appears to be very prom-
ising in patients with CAP due to influenza with suspected or 
confirmed co-infection with S. pneumoniae or S. aureus (MS-
SA or MRSA). Furthermore, a post hoc retrospective analysis of 
the subgroups of high-risk patients with CAP (n= 398) (PORT 
risk score >III, age >75 years, sepsis, COPD, bacteraemia, need 
for ICU) and HAP (n=307) (need for mechanical ventilation, 
APACHE score >15, age >75 years, bacteraemia, treatment in 
ICU, COPD, >10 comorbidities) from both of the aforemen-
tioned phase-III clinical trials has evaluated early clinical re-
sponse (3rd day in CAP and 4th day in HAP) for ceftobiprole 
versus the active comparator regimes, yielding overall similar 
results, with a trend towards better outcomes in the cefto-
biprole treated arm (numerical superiority assessed by 10% 
difference or CI not crossing 0). For this reason, high-risk pa-
tients with CAP and HAP (excluding VAP) may show earlier 
improvement upon ceftobiprole administration [25]. Case se-
ries presented at ECCMID 2019 on 57 patients with important 
DOSING ROUTES IN PNEUMONIA
Ceftobiprole should be administered at a dose of 500 mg 
every 8 h, infused over 2 h, in patients with normal kidney 
function. Ceftobiprole should be reconstituted with 10 ml ster-
ile saline or 5% dextrose. It is further diluted in 250 ml of 0.9% 
sodium chloride, 5% dextrose, or lactated ringers solution prior 
to intravenous infusion. 
Dosing in Special Patient Populations
• Patients with Kidney Failure: it is recommended to adjust 
the dose of ceftobiprole in patients with moderate to severe 
kidney failure. For patients with moderate deterioration (CrCl 
30 to <50 ml/min), the recommended dose is 500 mg adminis-
tered as intravenous infusion for 2 h every 12 h, while for those 
with severe deterioration (CrCl <30 ml/min), the recommended 
dose is 250 mg administered as intravenous infusion for 2 h 
every 12 h. For patients with terminal stage kidney disease, the 
recommended dose is 250 mg once every 24 h, regardless of 
whether or not they are undergoing haemodialysis.
• Treatment of Critically Ill Patients: antibiotics are among 
the most important and commonly prescribed medicines in 
the treatment of critically ill patients and β-lactams are the 
most widely used class of antibiotic. Pathophysiological fac-
tors in critically ill patients lead to altered pharmacokinetics 
and pharmacodynamics of β-lactams. In critically ill patients, 
capillary leak and oedema, fluid therapy, pleural effusion, as-
cites, permanent post-surgical drainage and hypo-albumi-
naemia may all increase the volume of distribution and cause 
dilution of antibiotics in plasma and extracellular fluids. Some 
pathophysiological factors may also improve (hyperdynamic 
condition in early stage sepsis, the use of haemodynamical-
ly active drugs) or reduce (kidney failure, bedridden patients) 
the concentrations of the antibiotic in plasma and extracellu-
lar fluid (with implications for MIC over time), prompting high 
intra and inter-patient variability and promoting the risk of 
antibiotic overdose. Extra-corporeal support techniques also 
contribute to the variability of antibiotic concentration [19, 
21]. There are very few studies that have investigated β-lactam 
PK/PD issues in critically ill patients with pneumonia. Rodvolt 
et al. [22] conducted a prospective, observational, pre-clinical 
murine model of pneumonia due to MRSA and a clinical study 
with 24 healthy volunteers who received ceftobiprole 500 mg 
over 2 h, every 8 h. Its conclusions were that for critically ill 
patients, particularly in the ICU, higher doses or longer infusion 
times (to prolong T>MIC), or both, will be required to guaran-
tee adequate achievement of objectives for 90% of critically ill 
patients with pneumonia due to MRSA. 
• Obese Patients: the physiological changes that obese patients 
present may influence the pharmacokinetics of antibiotics. One 
study compared the pharmacokinetics of a single intravenous in-
fusion of ceftobiprole 500 mg for 2 h in obese adults [body mass 
index (BMI)] [40 kg/m2] and those who were not obese (BMI 18-
30 kg/m2)[24]. The average BMI was 45.5 kg/m2 in the group with 
severe obesity (n = 12) compared to 24.0 kg/m2 in the non-obese 
group (n = 13); other baseline characteristics were similar in both 
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Lastly, considering that ceftobiprole shows potent in vit-
ro activity against the pathogens most commonly associated 
with HAP, above all S. aureus, non-ESBL Enterobacteriaceae, 
and P. aeruginosa, it has the potential to simplify empirical 
combination treatment with two antibiotics in a monotherapy 
regimen for HAP (excluding VAP).
REGISTRATIONS
Ceftobiprole medocaril has been approved in major Eu-
ropean countries for the treatment of CAP and HAP, exclud-
ing VAP [26, 27]. Ceftobiprole is currently in a phase 3 clinical 
program for registration in the U.S. In 2015 it was designated 
as an infectious disease product qualified for the treatment of 
lung and skin infections by the FDA [20]. This year ceftobiprole 
has been launched in Argentina [28]. 
CONCLUSIONS
One of the main challenges in the treatment of pneu-
monia (CAP and HAP) is overcoming the problems of re-
sistance, which have become so important and common in 
recent years. Ceftobiproles potent activity as a new-genera-
tion cephalosporin against broad spectrum of Gram-positive 
and Gram-negative bacteria has been demonstrated in two 
clinical trials, one on CAP and the other on HAP (excluding 
ventilation-associated pneumonia). Ceftobiprole is approved 
in major European countries as therapy for CAP and HAP 
(excluding VAP), and is designated as an infectious disease 
product qualified for the treatment of lung and skin infec-
tions by the FDA.
Ceftobiprole may be used in patients with CAP with sus-
pected or confirmed Staphylococcus aureus (MSSA or MRSA) 
as is the case with pneumonia due to the influenza virus in 
which S. pneumoniae may also be involved, and in patients 
with HAP to cover S. aureus, susceptible Pseudomonas aerugi-
nosa and non-ESBL Enterobacteriaceae.
Extended-spectrum coverage with ceftobiprole mono-
therapy may simplify empirical treatment in relation to com-
bined therapies against MRSA. 
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